Home » Newsletters » BioWorld Science

BioWorld Science

March 1, 2010

View Archived Issues

Truvada well tolerated in HIV-1-infected pregnant women and neonates

QNL-111 shown to inhibit HIV-1 DNA integration

Vicriviroc does not meet primary endpoint in two phase III trials in HIV

C5A inhibits HIV-1 and HSV in preclinical studies

Pfizer describes novel kappa opioid receptor antagonists

Novel serotonin 5-HT6 receptor antagonists patented by Janssen

Bristol-Myers Squibb discloses new transcription factor AP-1 inhibitors

Merck KGaA identifies novel PDK1 inhibitors

Ambit Biosciences claims novel Janus kinase inhibitors

Novel dual PI3K alpha and mTOR inhibitors described by S*BIO

Resverlogix activates first site in phase II ASSURE 1 trial of RVX-208 in ACS

Fourth quarter highlights at Merck & Co.

Adeona completes 50% of enrollment in Trimesta trial in multiple sclerosis

GlycoVaxyn begins clinical trial of bioconjugate GVXN-SD-133 Shigella vaccine

Akebia initiates phase Ib trial of AKB-6548 for anemia

Fluticasone nasal spray ineffective in irritant rhinitis in pilot trial

TMTI awards SIGA contract for development broad-spectrum antiviral ST-669

Global Health Ventures to begin European trials of X-Excite for erectile dysfunction

Corcept Therapeutics begins phase I CORT-108297 trial

Rockwell Medical reports phase IIb data on soluble ferric pyrophosphate

Johnson & Johnson reviews fourth quarter of 2009

Actelion reports on BUILD-3 trial of bosentan in idiopathic pulmonary fibrosis

FDA issues refuse to file letter to Adventrx on vinorelbine NDA

Virginia G. Piper Cancer Center and TGen begin phase I trial of Pharmacyclics' PCI-32765 in cancer

FDA grants marketing approval for Shire's VPRIV for type 1 GD

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...